☆ 4.7 Article

Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program

T. Bosse et al.

Summary: The RAINBO program aims to investigate molecular class-directed adjuvant treatment strategies for endometrial cancer, with the goal of improving clinical outcomes and reducing toxicity. It consists of four international clinical trials and an overarching research program to advance knowledge of predictive and prognostic markers.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)

Add to Collection

Article Oncology

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

Rebecca Kristeleit et al.

Summary: In patients with BRCA1 or BRCA2 mutated ovarian carcinoma, rucaparib demonstrated better progression-free survival compared to chemotherapy. The results of this study support rucaparib as an alternative treatment option for patients with relapsed BRCA-mutated ovarian carcinoma.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)

Bradley J. Monk et al.

Summary: This study evaluates the efficacy of rucaparib as a first-line maintenance treatment in ovarian cancer patients, showing significant benefits of rucaparib compared to placebo in patients with and without HRD.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway

Akiko Abe et al.

Summary: This study reviews the molecular features and hereditary tumor risk associated with several moderate-penetrance genes in epithelial ovarian cancer (EOC). Understanding the function and genetic mechanisms of these genes is important for predicting the genetic risk of EOC and selecting appropriate prevention and treatment strategies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andres Poveda et al.

Summary: Olaparib provided a median overall survival benefit of 12.9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Although statistical significance was not reached, these findings are arguably clinically meaningful and support the use of maintenance olaparib in these patients.

LANCET ONCOLOGY (2021)

Add to Collection

Article

Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®

Tracey White et al.

Oncotarget (2021)

Add to Collection

Review Biochemistry & Molecular Biology

POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes

Luigi Magrin et al.

Summary: POLE, POLD1, and NTHL1 genetic variants are associated with hereditary cancer predisposition, with different patterns of inheritance and potential impact on prognosis and treatment response in patients.

ONCOGENE (2021)

Add to Collection

Article Oncology

Multicentre randomized phase II trial of olaparib as maintenance therapy in platinum-sensitive advanced endometrial carcinoma: The GINECO-UTOLA study.

Florence Joly et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer

Kohei Nakamura et al.

JCO PRECISION ONCOLOGY (2020)

Add to Collection

Article Oncology

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

A. Gonzalez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

K. Moore et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

M. R. Mirza et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: A SEER analysis

Roberto Vargas et al.

GYNECOLOGIC ONCOLOGY (2014)

Add to Collection

Article Genetics & Heredity

ACMG clinical laboratory standards for next-generation sequencing

Heidi L. Rehm et al.

GENETICS IN MEDICINE (2013)

Add to Collection

Article Multidisciplinary Sciences

Integrated genomic characterization of endometrial carcinoma

Gad Getz et al.

NATURE (2013)

Add to Collection

Article Multidisciplinary Sciences

The BRCT domain is a phospho-protein binding domain

XC Yu et al.

SCIENCE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.